PDF(Pubmed)
Abstract：
Coronary sinus reducer (CSR) implantation is an emerging treatment option for patients with refractory angina. This condition represents a major global cardiovascular healthcare challenge, with patients experiencing chronic anginal symptoms that significantly impair their quality of life and for whom few effective treatments exist. The clinical burden of refractory angina is only set to grow because of improved survival from coronary artery disease, increased life expectancy and the presence of residual angina after percutaneous or surgical coronary revascularisation. Therefore, new, effective, evidence-based therapies are urgently needed. In this review, we highlight the unmet clinical needs of patients with refractory angina, discuss the development of the CSR device and review the preclinical and clinical evidence base underlying CSR implantation. In addition, we discuss the current role of CSR implantation in contemporary interventional practice, highlighting knowledge gaps and discussing areas of on-going research.
摘要：
冠状静脉窦减少器（CSR）植入是难治性心绞痛患者的新兴治疗选择。这种情况代表了全球心血管医疗保健的主要挑战。患有慢性心绞痛症状的患者严重损害了他们的生活质量，并且几乎没有有效的治疗方法。难治性心绞痛的临床负担只会因为冠状动脉疾病的生存率提高而增加，经皮或外科冠状动脉血运重建术后预期寿命延长和残余心绞痛的存在。因此,新,有效,迫切需要循证治疗。在这次审查中,我们强调了难治性心绞痛患者的临床需求未得到满足，讨论CSR装置的发展，并回顾CSR植入的临床前和临床证据基础。此外,我们讨论了CSR植入在当代介入实践中的当前作用，突出知识差距，讨论正在进行的研究领域。
